2007 April, Drug Discovery News – Editors Focus, by Randall C. Willis

“The thought arose as I listened to Dr. Michael May, president of Rimon Therapeutics, discuss his experiences in spinning out a company from an academic project. Aside from his comments about building networks and optimizing information flow, he described the early steps in the development of Theramers™, therapeutic polymers that the company has been promoting for wound healing. With one Theramer™, May and his colleagues discovered that something in the polymer itself inhibited matrix metalloproteases (MMPs), which are associated with tissue weakening.”
 

Click here for the complete article.